I-Mab Biopharma Revenue and Competitors
Estimated Revenue & Valuation
- I-Mab Biopharma's estimated annual revenue is currently $37M per year.
- I-Mab Biopharma's estimated revenue per employee is $155,000
Employee Data
- I-Mab Biopharma has 239 Employees.
- I-Mab Biopharma grew their employee count by 1% last year.
I-Mab Biopharma's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Chief Medical Officer | Reveal Email/Phone |
2 | Executive Director, Patent Litigation Counsel | Reveal Email/Phone |
3 | Business Development | Reveal Email/Phone |
I-Mab Biopharma Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $99.4M | 458 | 40% | N/A | N/A |
#2 | $20.6M | 133 | 22% | N/A | N/A |
#3 | $156.1M | 146 | -70% | $145M | N/A |
#4 | $3.5M | 45 | -25% | $150M | N/A |
#5 | $1.6M | 21 | 0% | $459.5M | N/A |
#6 | $67.3M | 310 | 16% | $180.7M | N/A |
#7 | $8.5M | 55 | -2% | N/A | N/A |
#8 | $256.3M | 1025 | 9% | $168.5M | N/A |
#9 | $2.8M | 18 | -33% | N/A | N/A |
#10 | $9.1M | 59 | -9% | N/A | N/A |
What Is I-Mab Biopharma?
I-Mab (Nasdaq: IMAB) is a dynamic, global biotech company exclusively focused on discovery, development and soon commercialization of novel or highly differentiated biologics in the therapeutic areas of immuno-oncology and autoimmune diseases. The Company's mission is to bring transformational medicines to patients around the world through innovation. I-Mab's innovative pipeline of more than 10 clinical and pre-clinical stage drug candidates is driven by the Company's Fast-to-PoC (Proof-of-Concept) and Fast-to-Market development strategies through internal R&D and global partnerships. The Company is on track to transitioning from a clinical stage biotech company toward a fully integrated global biopharmaceutical company with cutting-edge R&D capabilities, world-class GMP manufacturing facility and commercial capability. I-Mab has offices in Beijing, Shanghai, Hong Kong and Maryland, United States.
keywords:N/A
N/A
Total Funding
239
Number of Employees
$37M
Revenue (est)
1%
Employee Growth %
N/A
Valuation
N/A
Accelerator
I-Mab Biopharma News
Shanghai-based I-Mab is in talks with global drugmakers about a ... market for biopharma IPOs has deteriorated greatly over the past year.
Pre-Open Stock Movers 04/20: AlloVir, I-Mab Biopharma Gain; Netflix Plunges (more...) April 20, 2022 9:23 AM. Pre-Open Stock Movers: Netflix (NASDAQ: NFLX)...
SHANGHAI and GAITHERSBURG, Md., March 31, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical...
Other Companies in Shanghai
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $20.8M | 242 | 13% | $22M |
#2 | $48.8M | 243 | -8% | N/A |
#3 | $44.3M | 244 | -9% | N/A |
#4 | $19.1M | 250 | N/A | N/A |
#5 | $33.4M | 253 | 2% | N/A |